Last reviewed · How we verify
AK001
At a glance
| Generic name | AK001 |
|---|---|
| Sponsor | Allakos Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Multiple Doses in Patients With Nasal Polyposis (PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK001 CI brief — competitive landscape report
- AK001 updates RSS · CI watch RSS
- Allakos Inc. portfolio CI